

Chemicals/Finland, May 7, 2020 Company update

The story is not derailed

Exel's Q1 met expectations. The pandemic has so far had a limited impact on operations. Short-term demand outlook is uncertain, but we don't see long-term fundamentals impaired. Our TP is now EUR 5.50 (6.75), rating still BUY.

Strong development continued during Q1

Exel's EUR 27.8m Q1 revenue grew by 3% y/y and matched EUR 27.9m/27.2m Evli/cons estimates. The company updated its reporting structure, now disclosing revenue for seven customer industries instead of the previous three broad segments. Buildings & infrastructure and Wind power, which previously made up the Construction & Infrastructure segment, reported a combined EUR 12.0m in revenue, which was in line with our estimate (Wind power only grew by 1% y/y due to timing issues). Machinery & electrical, Transportation and Telecommunications, i.e. the former parts of Industrial Applications, reported a combined EUR 8.4m. This was less than we expected but Equipment & other industries and Defense made up with a total of EUR 7.4m. Adjusted EBIT, at EUR 2.1m, also met EUR 2.2m/2.0m Evli/cons estimates. ROCE increased to 12% from 3% a year ago and the US unit reached profitability. Order intake growth accelerated to 23% y/y pace and the EUR 34.5m in new orders meant order backlog stood at EUR 37.1m, up 50% y/y. A big US order is scheduled to be delivered through FY '20.

We now expect adjusted EBIT to increase to EUR 7.8m

Although strong development continued Exel is not immune to macro uncertainty and thus the company withdrew guidance. We revise our estimates down. We previously expected 6% top line growth for this year, and we have revised the figure down to 3%. We cut our FY '20 EBIT estimate down by EUR 0.9m to reflect potential operational challenges. In our opinion the long-term case remains intact. Exel also has a good liquidity situation. The EUR 10m overdraft facility was extended by two years.

We cut our TP due to significantly higher uncertainty

In our view higher multiples are justified by the fact that Exel has continued to perform according to expectations. Meanwhile the pandemic raises uncertainty even if development has remained good. We update our TP to EUR 5.50 (6.75) due to lowered estimates and higher uncertainty; yet in our view Exel still trades at relatively low multiples and we thus retain our BUY rating.



■ BUY □ HOLD ■ SELL

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2018	96.6	2.2	2.3%	-8.7	0.03	119.0	0.8	34.5	-18.3	0.18
2019	103.8	5.1	4.9%	0.7	0.20	32.5	1.0	21.0	0.9	0.18
2020E	106.6	7.6	7.1%	-7.3	0.33	14.4	0.9	12.6	-12.8	0.20
2021E	113.6	9.5	8.4%	5.1	0.50	9.6	0.8	9.7	8.9	0.25
2022E	120.5	10.2	8.5%	7.8	0.56	8.5	0.7	8.6	13.6	0.25
Market cap	o, EURm		57 G	earing 2020E,	0/0		136.6 CAGR	EPS 2019-2	2, %	40.8
Net debt 2	020E, EURm		38 P	rice/book 2020)E		2.0 CAGR	sales 2019-	22, %	5.1
Enterprise	value, EURm		96 D	ividend yield 2	2020E, %		4.2 ROE 2	020E, %		14.6
Total asset	s 2020E, EURn	n	97 T	ax rate 2020E,	0/0		31.8 ROCE	2020E, %		11.3
Goodwill 2	.020E, EURm		13 E	quity ratio 202	OE, %		28.9 PEG, F	P/E 20/CAGR		0.6



Chemicals/Finland, May 7, 2020 Company update

Estimates and peer group multiples

Exel Composites	2019	Q1/'20	Q2/'20E	Q3/'20E	Q4/'20E	2020E	2021E
Buildings and infrastructure	23.5	6.2	6.3	5.1	5.9	23.6	24.3
Equipment and other industries	18.6	6.1	5.5	4.2	4.4	20.2	21.2
Wind power	23.6	5.8	6.6	6.5	7.1	26.0	29.1
Machinery and electrical	14.4	3.8	3.9	3.7	3.2	14.5	15.1
Transportation	13.1	3.4	3.4	2.8	2.9	12.5	13.4
Defense	2.3	1.3	0.8	0.5	0.6	3.2	3.5
Telecommunications	8.2	1.2	1.4	1.0	3.0	6.6	7.0
Revenue	103.8	27.8	27.9	23.8	27.1	106.6	113.6
change, %	7 %	3 %	<i>5</i> %	1 %	2 %	3 %	7 %
Adjusted EBIT	7.2	2.1	2.0	1.7	2.0	7.8	9.5
•			2.0	1.7	2.0		9.5
EBIT	5.1	1.9				7.6	
-margin, %	6.9 %	7.5 %	7.2 %	7.1 %	7.4 %	7.3 %	8.4 %
-margin (reported), %	4.9 %	6.7 %				7.1 %	

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	19	20	21	19	20	21	19	20	21
Gurit Holding	596	10.4x	9.2x	9.0x	13.6x	11.8x	11.6x	9.9 %	9.6 %	9.8 %
Hexagon Composites	446	23.4x	18.8x	12.4x	87.0x	52.3x	21.5x	2.6 %	3.4 %	6.8 %
Hexcel	2140	12.9x	9.4x	8.3x	17.3x	16.0x	12.7x	18.1 %	12.1 %	14.1 %
PolyOne	1820	10.0x	5.6x	4.8x	12.0x	8.0x	6.3x	9.6 %	8.2 %	10.0 %
SGL Carbon	331	10.4x	9.5x	6.3x	20.8x		19.2x	3.7 %	-0.3 %	3.5 %
TPI Composites	545	10.4x	8.4x	5.1x	44.5x	24.5x	9.3x	1.3 %	2.2 %	4.9 %
Peer Group Average	979	12.9x	10.2x	7.6x	32.5x	22.5x	13.5x	7.5 %	5.9 %	8.2 %
Peer Group Median	571	10.4x	9.3x	7.3x	19.1x	16.0x	12.2x	6.7 %	5.8 %	8.3 %
Exel Composites (Evli est.)	57	10.0x	7.0x	6.0x	21.0x	12.6x	9.7x	4.9 %	7.1 %	8.4 %
Exel Composites prem./disc. to peer media	an	-4 %	-24 %	-18 %	10 %	-21 %	-20 %	-26 %	22 %	1 %

Exel Composites prem./disc. to peer median

Source FactSet, Evli Research

Chemicals/Finland, May 7, 2020 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	4.80 PV of Free Cash Flow	55 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	7.76 PV of Horizon value	68 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	61.7 Unconsolidated equity	O Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	8.6 Marketable securities	7 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	7.0 Debt - dividend	-38 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	55.4 Value of stock	92 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2019	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	Horizon
Net sales	104	107	114	120	128	134	138	142	144	147	149	152
Sales growth, %	7.5	2.7	6.6	6.0	6.0	5.0	3.0	2.5	2.0	2.0	1.5	1.5
Operating income (EBIT)	5	8	10	10	11	11	12	12	12	13	13	13
Operating income margin, %	4.9	7.1	8.4	8.5	8.5	8.5	8.5	8.5	8.5	8.5	8.5	8.5
+ Depreciation+amort.	6	6	6	8	7	7	7	7	6	5	5	
EBITDA	11	14	16	18	18	18	19	19	18	18	18	
- Paid taxes	-2	-2	-2	-2	-2	-2	-2	-3	-3	-3	-3	
- Change in NWC	1	0	-1	-1	-1	-1	-1	-1	0	0	0	
NWC / Sales, %	14.1	14.1	14.2	14.3	14.3	14.4	14.4	14.4	14.4	14.5	14.5	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-6	-15	-4	-4	-4	-5	-4	- 5	-5	- 5	-5	
opCAPEX / Sales, %	7.3	15.8	5.2	4.9	4.8	4.7	4.5	4.4	3.7	3.7	3.6	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	3	-4	8	11	10	11	11	11	10	10	10	151
= Discounted FCFF		-4	7	9	8	7	7	6	5	5	5	68
		-			-	-		-				
= DFCF min WACC		-4	7	9	8	7	7	7	6	5	5	77
= DFCF max WACC		-4	7	9	8	7	7	6	5	5	5	61

Chemicals/Finland, May 7, 2020 Company update

INTERIM FIGURES

	_			_						_	_	
EVLI ESTIMATES, EURm	2019Q1	2019Q2	2019Q3	2019Q4	2019	2020Q1	2020Q2E	2020Q3E	2020Q4E	2020E	2021E	2022E
Net sales	27.1	26.5	23.6	26.6	103.8	27.8	27.9	23.8	27.1	106.6	113.6	120.5
EBITDA	1.8	3.4	2.9	2.6	10.7	3.4	3.5	3.2	3.5	13.6	15.6	18.3
EBITDA margin (%)	6.6	13.0	12.1	9.8	10.3	12.1	12.5	13.4	12.9	12.7	13.8	15.2
EBIT	0.4	2.1	1.5	1.1	5.1	1.9	2.0	1.7	2.0	7.6	9.5	10.2
EBIT margin (%)	1.5	7.9	6.4	4.1	4.9	6.7	7.2	7.1	7.4	7.1	8.4	8.5
Net financial items	-0.2	-0.2	0.0	-0.8	-1.2	-0.6	-0.4	-0.4	-0.4	-1.8	-1.6	-1.8
Pre-tax profit	0.2	1.9	1.5	0.3	3.9	1.3	1.6	1.3	1.6	5.8	7.9	8.5
Tax	-0.6	-0.3	-0.7	0.1	-1.5	-0.6	-0.4	-0.4	-0.4	-1.8	-2.0	-1.8
Tax rate (%)	300.0	15.8	46.7	-33.3	38.5	49.4	25.0	30.8	25.0	31.8	25.2	21.0
Net profit	-0.4	1.6	0.8	0.4	2.4	0.7	1.2	0.9	1.2	4.0	5.9	6.7
EPS	-0.03	0.13	0.07	0.03	0.20	0.06	0.10	0.08	0.10	0.33	0.50	0.56
EPS adjusted (diluted no. of shares)	-0.03	0.13	0.07	0.03	0.20	0.06	0.10	0.08	0.10	0.33	0.50	0.56
Dividend per share	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	0.00	0.20	0.25	0.25
SALES, EURm												
Exel Composites	27.1	26.5	23.6	26.6	103.8	27.8	27.9	23.8	27.1	106.6	113.6	120.5
Total	27.1	26.5	23.6	26.6	103.8	27.8	27.9	23.8	27.1	106.6	113.6	120.5
SALES GROWTH, Y/Y %												
Exel Composites	26.0	4.7	2.2	-0.4	7.5	2.6	5.3	0.8	1.9	2.7	6.6	6.0
Total	26.0	4.7	2.2	-0.4	7.5	2.6	5.3	0.8	1.9	2.7	6.6	6.0
EBIT, EURm												
Exel Composites	0.4	2.1	1.5	1.1	5.1	1.9	2.0	1.7	2.0	7.6	9.5	10.2
Total	0.4	2.1	1.5	1.1	5.1	1.9	2.0	1.7	2.0	7.6	9.5	10.2
EBIT margin, %												
Exel Composites	1.5	7.9	6.4	4.1	4.9	6.7	7.2	7.1	7.4	7.1	8.4	8.5
Total	1.5	7.9	6.4	4.1	4.9	6.7	7.2	7.1	7.4	7.1	8.4	8.5

Chemicals/Finland, May 7, 2020 Company update

INCOME STATEMENT, EURm	2015	2016	2017	2018	2019	2020E	2021E	2022E
Sales	80.2	73.1	86.3	96.6	103.8	106.6	113.6	120.5
Sales growth (%)	1.1	-8.9	18.1	11.9	7.5	2.7	6.6	6.0
EBITDA	7.3	3.8	9.3	7.7	10.7	13.6	15.6	18.3
EBITDA margin (%)	9.1	5.2	10.8	8.0	10.3	12.7	13.8	15.2
Depreciation	-2.9	-3.2	-3.2	-5.5	-5.6	-6.0	-6.1	-8.1
EBITA	4.4	0.6	6.1	2.2	5.1	7.6	9.5	10.2
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	4.4	0.6	6.1	2.2	5.1	7.6	9.5	10.2
EBIT margin (%)	5.5	0.8	7.1	2.3	4.9	7.1	8.4	8.5
Reported EBIT	4.0	-1.2	6.1	2.2	5.1	7.6	9.5	10.2
EBIT margin (reported) (%)	5.0	-1.6	7.1	2.3	4.9	7.1	8.4	8.5
Net financials	-0.2	-0.1	-0.7	-0.5	-1.2	-1.8	-1.6	-1.8
Pre-tax profit	4.2	0.5	5.4	1.7	3.9	5.8	7.9	8.5
Taxes	-1.4	-0.2	-1.2	-1.3	-1.5	-1.8	-2.0	-1.8
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	2.4	-1.4	4.2	0.4	2.4	4.0	5.9	6.7
Cash NRIs	-0.4	-1.8	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	15	17	16	21	23	33	33	30
Goodwill	10	10	13	13	13	13	13	13
Right of use assets	0	0	0	5	5	5	5	5
Inventory	10	9	12	15	17	17	18	20
Receivables	12	10	15	20	20	21	22	23
Liquid funds	8	7	8	5	7	7	8	8
Total assets	54	54	64	79	85	97	100	101
Liabilities								
Shareholder's equity	31	27	29	26	26	28	32	35
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	0	0	3	4	5	5	5
Deferred taxes	1	1	0	0	0	0	0	0
Interest bearing debt	8	14	16	30	32	41	38	34
Non-interest bearing current liabilities	14	12	18	18	21	22	23	24
Other interest-free debt	1	1	0	2	2	2	2	2
Total liabilities	54	54	64	79	85	97	100	101
CASH FLOW, EURm								
+ EBITDA	7	4	9	8	11	14	16	18
- Net financial items	0	0	-1	0	-1	-2	-2	-2
- Taxes	-2	0	-1	-2	-2	-2	-2	-2
- Increase in Net Working Capital	-2	1	-3	-4	1	0	-1	-1
+/- Other	1	-1	1	0	0	0	0	0
= Cash flow from operations	3	3	5	1	8	10	11	14
- Capex	-4	-3	-3	-10	-8	-17	-6	-6
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-1	0	1	-9	1	-7	5	8
+/- New issues/buybacks	1	0	-1	0	0	0	0	0
- Paid dividend	-2	-3	-1	-4	-2	-2	-2	-3
+/- Other	2	2	1	9	3	10	-2	-4
Change in cash	0	-1	0	-3	2	0	0	0

Chemicals/Finland, May 7, 2020 Company update

KEY FIGURES	2016	2017	2018	2019	2020E	2021E	2022E
M-cap	60	78	48	78	57	57	57
Net debt (excl. convertibles)	6	9	28	29	38	36	31
Enterprise value	66	87	76	107	96	93	88
Sales	73	86	97	104	107	114	120
EBITDA	4	9	8	11	14	16	18
EBIT	1	6	2	5	8	10	10
Pre-tax	1	5	2	4	6	8	8
Earnings	0	4	0	2	4	6	7
Equity book value (excl. minorities)	27	29	26	26	28	32	35
Valuation multiples							
EV/sales	0.9	1.0	0.8	1.0	0.9	0.8	0.7
EV/EBITDA	17.3	9.3	9.9	10.0	7.0	5.9	4.8
EV/EBITA	109.9	14.2	34.5	21.0	12.6	9.7	8.6
EV/EBIT	109.9	14.2	34.5	21.0	12.6	9.7	8.6
EV/OCF	21.3	17.7	84.3	12.9	10.0	8.5	6.4
EV/FCFF	-38.8	-28.4	-6.6	32.5	-22.8	11.8	8.2
P/FCFE	0.0	55.8	-5.5	110.9	-7.8	11.3	7.4
P/E	164.3	18.6	119.0	32.5	14.4	9.6	8.5
r/c P/B	2.2				2.0		
•		2.7	1.8	3.0		1.8	1.6
Target EV/EBITDA	0.0	0.0	0.0	0.0	7.7	6.5	5.3
Target EV/EBIT	0.0	0.0	0.0	0.0	13.7	10.6	9.4
Target EV/FCF	0.0	0.0	0.0	0.0	-14.2	20.0	12.4
Target P/B	0.0	0.0	0.0	0.0	2.3	2.1	1.8
Target P/E	0.0	0.0	0.0	0.0	16.5	11.0	9.8
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.03	0.35	0.03	0.20	0.33	0.50	0.56
Operating cash flow per share	0.26	0.41	0.08	0.70	0.80	0.92	1.15
Free cash flow per share	0.00	0.12	-0.73	0.06	-0.61	0.43	0.65
Book value per share	2.24	2.42	2.16	2.21	2.36	2.66	2.98
Dividend per share	0.10	0.30	0.18	0.18	0.20	0.25	0.25
Dividend payout ratio, %	327.2	85.0	535.4	89.2	60.0	50.0	44.4
Dividend yield, %	2.0	4.6	4.5	2.7	4.2	5.2	5.2
FCF yield, %	0.0	1.8	-18.3	0.9	-12.8	8.9	13.6
Efficiency measures							
ROE	1.3	45.0		9.2	14.6	19.9	20.0
	1.3	15.2	1.5	9.2	1 1.0		
ROCE	1.8	15.2 14.6	1.5 4.5	9.2 8.6	11.3	13.0	13.9
ROCE Financial ratios							13.9
							13.9
Financial ratios	1.8	14.6	4.5	8.6	11.3	13.0	
Financial ratios Inventories as % of sales	1.8	13.5	4.5 15.7	8.6	11.3	13.0	16.3
Financial ratios Inventories as % of sales Receivables as % of sales	1.8 12.0 14.0	14.6 13.5 17.1	15.7 20.8	16.3 19.2	11.3 16.3 19.2	13.0 16.3 19.2	16.3 19.2
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	1.8 12.0 14.0 17.0	14.6 13.5 17.1 21.4	4.5 15.7 20.8 19.2	16.3 19.2 20.2	11.3 16.3 19.2 20.2	13.0 16.3 19.2 20.2	16.3 19.2 20.2
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	1.8 12.0 14.0 17.0 9.0	13.5 17.1 21.4 9.3	4.5 15.7 20.8 19.2 16.1	16.3 19.2 20.2 14.1	11.3 16.3 19.2 20.2 14.1	13.0 16.3 19.2 20.2 14.2	16.3 19.2 20.2 14.3
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	1.8 12.0 14.0 17.0 9.0 4.2 4.2	13.5 17.1 21.4 9.3 4.1 4.1	15.7 20.8 19.2 16.1 9.9 9.9	16.3 19.2 20.2 14.1 7.3 7.3	11.3 16.3 19.2 20.2 14.1 15.8 15.8	13.0 16.3 19.2 20.2 14.2 5.2 5.2	16.3 19.2 20.2 14.3 4.9 4.9
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	1.8 12.0 14.0 17.0 9.0 4.2	13.5 17.1 21.4 9.3 4.1	15.7 20.8 19.2 16.1 9.9 9.9 -1.5	16.3 19.2 20.2 14.1 7.3	11.3 16.3 19.2 20.2 14.1 15.8	13.0 16.3 19.2 20.2 14.2 5.2	16.3 19.2 20.2 14.3 4.9
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	1.8 12.0 14.0 17.0 9.0 4.2 4.2 -0.4 1.6	13.5 17.1 21.4 9.3 4.1 4.1 -0.3 0.9	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5 3.7	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	11.3 16.3 19.2 20.2 14.1 15.8 15.8 -0.3 2.8	13.0 16.3 19.2 20.2 14.2 5.2 5.2 0.5 2.3	16.3 19.2 20.2 14.3 4.9 4.9 0.6 1.7
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	1.8 12.0 14.0 17.0 9.0 4.2 4.2 -0.4	13.5 17.1 21.4 9.3 4.1 4.1 -0.3	15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	11.3 16.3 19.2 20.2 14.1 15.8 15.8 -0.3	13.0 16.3 19.2 20.2 14.2 5.2 5.2 0.5	16.3 19.2 20.2 14.3 4.9 4.9 0.6

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 7, 2020 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Skandinaviska Enskilda Banken AB (Nom. reg.)	1,733,367	8.320	14.6%
Nordea Bank ABP (Nom. reg.)	1,034,258	4.964	8.7%
Sijoitusrahasto Taaleritehdas Mikro Markka	750,000	3.600	6.3%
OP-Finland Small Firms Fund	598,259	2.872	5.0%
Danske Invest Finnish Equity Fund	346,650	1.664	2.9%
Phoebus Fund	290,000	1.392	2.4%
Säästöpankki Pienyhtiöt	288,710	1.386	2.4%
Nelimarkka Heikki Antero	242,836	1.166	2.0%
Ilmarinen Mutual Pension Insurance Company	242,733	1.165	2.0%
Veritas Pension Insurance Company Ltd.	226,163	1.086	1.9%
Ten largest	5,752,976	27.614	48%
Residual	6,143,867	29.491	52%
Total	11,896,843	57.105	100%

EARNINGS CALENDAR		
July 21, 2020	Q2 report	
October 30, 2020	Q3 report	
OTHER EVENTS		

COMPANY	MUCCEL	LANIEOLIC

CEO: Riku Kytömäki CFO: Mikko Kettunen IR: Noora Koikkalainen

Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, May 7, 2020 Company update

DEFINITIONS

Profit before extraord. items and taxes- income taxes + minority interest Number of shares DPS Dividend for the financial period per share
Dividend for the financial period per share
OCF (Operating cash flow)
EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
FCF (Free cash flow)
Operating cash flow – operative CAPEX – acquisitions + divestments
FCF yield, %
Free cash flow Market cap
Operative CAPEX/sales
Capital expenditure – divestments – acquisitions Sales
Net working capital
Current assets – current liabilities
Capital employed/Share
Total assets – non-interest bearing debt Number of shares
Gearing
<u>Net debt</u> Equity
Debt/Equity, %
Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Equity ratio, %
Shareholders' equity + minority interest + taxed provisions Total assets - interest-free loans
CAGR, %
Cumulative annual growth rate = Average growth per year

Chemicals/Finland, May 7, 2020 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 timer per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 1st of February 2019. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [7.5.2020, 9:15]. This report has been published on [7.5.2020, 9:30].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or EVIi. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 7, 2020 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, May 7, 2020 Company update

Contact information SALES, TRADING AND RESEARCH

Equity Sales		Trading		ETFs and Derivatives	
Ari Laine Lauri Ahokanto Niclas Henelius	+358 9 4766 9115 +358 9 4766 9117 +358 9 4766 9116	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Roankanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120	Joachim Dannberg Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9130
Structured Investments		Equity Research			
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919		
Evli Investment Solutions					
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669				



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001